Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice

AAPS Journal

Volumn 15, Issue 3, 2013, Pages 744-752

  Gao, Mingming ^a   Liu, Dexi ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

AMPK; fatty liver; gluconeogenesis; lipogenesis; liver X receptor; resveratrol; T0901317

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ACETYL COENZYME A CARBOXYLASE; CHOLESTEROL; COMPOUND C; CYTOCHROME P450 1A1; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RESVERATROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABCA1 GENE; ABCG1 GENE; ACC GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CHREBP GENE; CONTROLLED STUDY; CYP7A1 GENE; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATTY LIVER; G6P GENE; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; LIPOGENESIS; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PEPCK GENE; SREBP 1C GENE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; FATTY LIVER; HEPATOCYTES; HYDROCARBONS, FLUORINATED; MALE; MICE; MICE, INBRED C57BL; ORPHAN NUCLEAR RECEPTORS; STILBENES; SULFONAMIDES;

EID: 84879795568     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9473-7     Document Type: Article

References (36)

1. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996;383(6602):728-31.
2. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 1998;93(5):693-704.
3. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7(1):161-71.
4. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99(11):7604-9.
5. Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver X receptor (LXR). Diabetes. 2004;53 Suppl 1:S36-42.
6. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, Molteni V, et al. The nuclear receptor LXR is a glucose sensor. Nature. 2007;445(7124):219-23.
7. Cao GQ, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, et al. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem. 2003;278(2):1131-6.
8. Liu YJ, Yan CY, Wang Y, Nakagawa Y, Nerio N, Anghel A, et al. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology. 2006;147(11):5061-8.
9. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li LP, et al. Role of LXRs in control of lipogenesis. Gene Dev. 2000;14(22):2831-8.
10. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14(22):2819-30.
11. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis - the carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007;282(1):743-51.
12. Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res. 2008;38(11):1122-9.
13. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol. 2002;92(6):2475-82.
14. Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, Zhou XH. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun. 2009;380(3):644-9.
15. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
16. Farina A, Ferranti C, Marra C. An improved synthesis of resveratrol. Nat Prod Res. 2006;20(3):247-52.
17. Wang H, Liu L, Guo YX, Dong YS, Zhang DJ, Xiu ZL. Biotransformation of piceid in Polygonum cuspidatum to resveratrol by Aspergillus oryzae. Appl Microbiol Biotechnol. 2007;75(4):763-8.
18. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation. 2007;30(1-2):1-6.
19. Szmitko PE, Verma S. Cardiology patient pages. Red wine and your heart. Circulation. 2005;111(2):e10-1.
20. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs. 2008;9(4):371-8.
21. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8(2):157-68.
22. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo HB, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421-33.
23. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem. 1978;90(1):420-6.
24. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, et al. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes. 2005;29(7):864-71.
25. Gupta S, Pandak WM, Hylemon PB. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun. 2002;293(1):338-43.
26. Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie. 2005;87(1):81-6.
27. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab. 2003;285(4):E685-92.
28. Yoon JC, Puigserver P, Chen GX, Donovan J, Wu ZD, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131-8.
29. Gao M, Liu D. The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance. AAPS J. 2013;15(1):258-66.
30. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA. 2003;100(9):5419-24.
31. Ajmo JM, Liang XM, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver. 2008;295(4):G833-42.
32. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005;280(17):17187-95.
33. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005;280(17):17038-45.
34. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42.
35. Hou XY, Xu SQ, Maitland-Toolan KA, Sato K, Jiang BB, Ido YS, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. 2008;283(29):20015-26.
36. Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675-90.